This report provides an overview of global regenerative medicine clinical trials and an analysis of any trends through the years.
Scope
- The clinical trials data used for these analyses were extracted from the publisher's Clinical Trials Database. The data was captured in the database as of September 8, 2022. The data has been analyzed by trial start year, phase, status, sponsor type, geography, single-country vs. multinational, virtual components, therapy area, indication, reasons for discontinuation, endpoint status, sponsors, and drugs
Reasons to Buy
- Trends of regenerative medicine trials through the years
- Comparison of trials by sponsor type
- Can view top therapy areas, indications, geographies and sponsors
- Focus on the usage of decentralized clinical trials/virtual components
- Analysis of top drugs used
Table of Contents
- Executive Summary
- Introduction
- The Expanding Landscape of Regenerative Medicine
- Phase II Trials Top Regenerative Medicine Trials
- Industry-Sponsored Trials Dominate
- North America and the US Saw the Most Trials
- North America Has the Most Single-Country Trials While Europe Has the Most Multinational
- Virtual Components Used Less in Regenerative Medicine Clinical Trials
- Cardiovascular Is the Most Researched Therapy Area
- Low Accrual Rate Is the Leading Cause of Trial Termination
- Phase II and Industry-Sponsored Trials Achieved Their Endpoints More Frequently
- Mesoblast Is the Top Industry Sponsor
- Foundation for Orthopedics and Regenerative Medicine Is the Top Non-industry Sponsor
- Tisagenlecleucel Is the Top Drug Used in Regenerative Medicine Clinical Trials
- Key Findings
- Appendix
Figure 1: Number of regenerative medicine clinical trials, by trial start year
Figure 2: Regenerative medicine clinical trials, by phase and status
Figure 3: Number of regenerative medicine clinical trials, by sponsor type and year
Figure s 4 & 5: Number of regenerative medicine clinical trials, by region and country
Figure 6: Single-country and multinational regenerative clinical trials, by region
Figure 7: Virtual components used in regenerative medicine clinical trials, by trial status
Figure s 8 & 9: Regenerative medicine clinical trials, by therapy area and indication
Figure 10: Regenerative medicine clinical trials, by termination reason
Figure 11: Endpoint status of completed regenerative medicine clinical trials, by phase and sponsor type
Figure 12: Top industry sponsors for regenerative medicine clinical trials, by trial status
Figure 13: Top non-industry sponsors for regenerative medicine clinical trials, by trial status
Figure 14: Top drugs for regenerative medicine clinical trials, by trial status
